EA200970533A1 - Жидкие композиции антител против бешенства - Google Patents

Жидкие композиции антител против бешенства

Info

Publication number
EA200970533A1
EA200970533A1 EA200970533A EA200970533A EA200970533A1 EA 200970533 A1 EA200970533 A1 EA 200970533A1 EA 200970533 A EA200970533 A EA 200970533A EA 200970533 A EA200970533 A EA 200970533A EA 200970533 A1 EA200970533 A1 EA 200970533A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liquid compositions
against rabies
bodies against
rabies
pharmaceutical compositions
Prior art date
Application number
EA200970533A
Other languages
English (en)
Other versions
EA017549B1 (ru
Inventor
Александер Бертольд Хендрик Баккер
Виллем Эгберт Мариссен
Original Assignee
Круселл Холланд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В. filed Critical Круселл Холланд Б.В.
Publication of EA200970533A1 publication Critical patent/EA200970533A1/ru
Publication of EA017549B1 publication Critical patent/EA017549B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим композициям антител, в частности к жидким фармацевтическим композициям, содержащим антитела против вируса бешенства. Композиции могут использоваться для профилактики бешенства после контакта с источником заражения.
EA200970533A 2006-12-05 2007-12-04 Стабильные жидкие композиции антител против вируса бешенства EA017549B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87289206P 2006-12-05 2006-12-05
EP06125400 2006-12-05
PCT/EP2007/063244 WO2008068246A1 (en) 2006-12-05 2007-12-04 Liquid anti-rabies antibody formulations

Publications (2)

Publication Number Publication Date
EA200970533A1 true EA200970533A1 (ru) 2009-10-30
EA017549B1 EA017549B1 (ru) 2013-01-30

Family

ID=39092188

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970533A EA017549B1 (ru) 2006-12-05 2007-12-04 Стабильные жидкие композиции антител против вируса бешенства

Country Status (13)

Country Link
US (1) US7959922B2 (ru)
EP (1) EP2088997B1 (ru)
JP (1) JP5410985B2 (ru)
KR (1) KR101522036B1 (ru)
CN (1) CN101557799B (ru)
AU (1) AU2007328960B2 (ru)
CA (1) CA2668947C (ru)
CU (1) CU23795A3 (ru)
EA (1) EA017549B1 (ru)
IL (1) IL199004A (ru)
MX (1) MX2009005414A (ru)
WO (1) WO2008068246A1 (ru)
ZA (1) ZA200902772B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004251890B2 (en) 2003-06-25 2010-09-23 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
EP1749029B1 (en) * 2004-05-27 2011-03-09 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
AU2007255384B2 (en) * 2006-06-06 2012-09-27 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
KR101522036B1 (ko) 2006-12-05 2015-05-20 크루셀 홀란드 비.브이. 액체 항-광견병 항체 조성물
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
IN2014CN03555A (ru) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
BR112014021308B1 (pt) * 2012-03-07 2022-08-30 Eli Lilly And Company Formulações farmacêuticas de anticorpos
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
JP7159642B2 (ja) * 2018-06-26 2022-10-25 東ソー株式会社 カラムの抗体に対する保持力の測定方法
TW202214694A (zh) 2020-06-12 2022-04-16 大陸商南京維立志博生物科技有限公司 結合ｔｎｆｒ２的抗體及其用途
CN114748618B (zh) * 2022-04-02 2024-07-19 重庆智翔金泰生物制药股份有限公司 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402029B1 (en) 1989-06-08 1994-01-12 The Wistar Institute Monoclonal antibodies for post exposure treatment of rabies
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
JP2001512560A (ja) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
NZ531291A (en) 2001-08-21 2006-02-24 Univ Jefferson Recombinant anti rabies antibodies MAb JB.1 and Mab 57 and compositions and methods for making and using the same
CA2965865C (en) 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
WO2005023849A2 (en) 2003-09-04 2005-03-17 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
EP1686137A4 (en) * 2003-10-09 2009-10-28 Chugai Pharmaceutical Co Ltd PROCESS FOR STABILIZING PROTEIN SOLUTIONS
EP1688432B1 (en) * 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Igm high concentration stabilized solution
ES2553987T3 (es) * 2003-12-25 2015-12-15 Kyowa Hakko Kirin Co., Ltd. Preparación farmacéutica de base acuosa estable que contiene anticuerpo
EP1749029B1 (en) * 2004-05-27 2011-03-09 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
CA2604840A1 (en) * 2005-04-18 2006-10-26 Xtl Biopharmaceuticals Ltd. Stabilized anti-hepatitis b (hbv) antibody formulations
KR101522036B1 (ko) 2006-12-05 2015-05-20 크루셀 홀란드 비.브이. 액체 항-광견병 항체 조성물

Also Published As

Publication number Publication date
AU2007328960B2 (en) 2013-01-17
IL199004A0 (en) 2010-02-17
KR20090089881A (ko) 2009-08-24
KR101522036B1 (ko) 2015-05-20
CU23795A3 (es) 2012-03-15
IL199004A (en) 2015-10-29
CN101557799A (zh) 2009-10-14
AU2007328960A1 (en) 2008-06-12
JP5410985B2 (ja) 2014-02-05
JP2010511665A (ja) 2010-04-15
US20100034829A1 (en) 2010-02-11
EP2088997B1 (en) 2016-08-24
EP2088997A1 (en) 2009-08-19
WO2008068246A1 (en) 2008-06-12
MX2009005414A (es) 2009-06-01
CA2668947C (en) 2017-02-07
US7959922B2 (en) 2011-06-14
CA2668947A1 (en) 2008-06-12
CN101557799B (zh) 2012-08-22
ZA200902772B (en) 2012-09-26
EA017549B1 (ru) 2013-01-30

Similar Documents

Publication Publication Date Title
EA200970533A1 (ru) Жидкие композиции антител против бешенства
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
BR112013032434A2 (pt) restauração dentária, método para sua produção e vidro cerâmico
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
EA201791850A1 (ru) Борсодержащие малые молекулы
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA201201016A1 (ru) Антидоты антикоагулянтов
BRPI0909084A2 (pt) Composição líquida, e, composto de peptídeo.
EA201270423A1 (ru) Ингибиторы протеазы hcv
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
EA201171246A1 (ru) Содержащая трегалулозу композиция, ее получение и применение
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
BR112013028679A2 (pt) inibidores do vírus da hepatite c
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
DK1987357T3 (da) Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf